Provided by Tiger Fintech (Singapore) Pte. Ltd.

ReShape Lifesciences, Inc.

0.3097
-0.0534-14.71%
Post-market: 0.30990.0002+0.06%19:58 EDT
Volume:4.48M
Turnover:1.42M
Market Cap:3.49M
PE:-0.02
High:0.3606
Open:0.3500
Low:0.3016
Close:0.3631
Loading ...

US Stocks Likely To Open Lower Ahead Of March Inflation Release: Expert Highlights 'Fairly Weak Returns' After 5%+ Gains In S&P 500

Benzinga
·
10 Apr

ReShape Lifesciences to Bring Motion Informatics' Neuromuscular Rehabilitation Devices to US

MT Newswires Live
·
10 Apr

ReShape Lifesciences enters agreement with Haifa

TIPRANKS
·
10 Apr

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

GlobeNewswire
·
10 Apr

ReShape Lifesciences FY24 EPS $(13.83); Revenue $8.01M Down From $8.68M YoY

Benzinga
·
08 Apr

ReShape Lifesciences Inc: Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys Remain on Track

THOMSON REUTERS
·
08 Apr

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
08 Apr

Press Release: ReShape Lifesciences(R) Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

Dow Jones
·
08 Apr

ReShape Lifesciences : Receives Notice of Allowance for U.S. Patent Related to Proprietary Diabetes Neuromodulation Technology

THOMSON REUTERS
·
10 Mar

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

GlobeNewswire
·
10 Mar

ReShape Lifesciences signs distribution agreement with Liaison Medical

TIPRANKS
·
25 Feb

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for Its Next-Generation Lap-Band® 2.0 Flex

THOMSON REUTERS
·
25 Feb

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

GlobeNewswire
·
25 Feb

BUZZ-ReShape Lifesciences slumps after $6 mln public offering

Reuters
·
18 Feb

BRIEF-Reshape Lifesciences Says Pricing Of Upsized $6.0 Million Public Offering

Reuters
·
16 Feb

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

THOMSON REUTERS
·
16 Feb

ReShape Lifesciences Inc - Prices Public Offering of 2,575,107 Units at $2.33 per Unit

THOMSON REUTERS
·
16 Feb

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

GlobeNewswire
·
16 Feb

ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

GlobeNewswire
·
03 Feb

ReShape Lifesciences: in Process of Responding to Comments From SEC Regarding Agreement With Vyome

THOMSON REUTERS
·
13 Jan